Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice

Journal of Virology

Volumn 80, Issue 19, 2006, Pages 9391-9401

  Andrei, Graciela ^a   Gammon, Don B ^b   Fiten, Pierre ^a   De Clercq, Erik ^a   Opdenakker, Ghislain ^a   Snoeck, Robert ^a   Evans, David H ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA POLYMERASE; EXONUCLEASE; VIRUS DNA;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; E9L GENE; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS MUTATION; VIRUS VIRULENCE;

ALLELES; ANIMALS; BASE SEQUENCE; BIOLOGICAL MARKERS; CELL LINE; CYTOSINE; DNA, RECOMBINANT; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PHOSPHONIC ACIDS; PROTEIN STRUCTURE, QUATERNARY; VACCINIA VIRUS; VIRULENCE;

ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 33748946630     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00605-06     Document Type: Article

References (39)

1. Andrei, G., R. Snoeck, E. De Clercq, R. Esnouf, P. Fiten, and G. Opdenakker. 2000. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81:639-648.
2. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57:13-23.
3. Baker, R. P., and L. J. Reha-Krantz. 1998. Identification of a transient excision intermediate at the crossroads between DNA polymerase extension and proofreading pathways. Proc. Natl. Acad. Sci. USA 95:3607-3512.
4. Bestman-Smith, J., and G. Boivin. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77:7820-7829.
5. Blanco, L., A. Bernad, and M. Salas. 1992. Evidence favouring the hypothesis of a conserved 3′-5′ exonuclease active site in DNA-dependent DNA polymerases. Gene 112:139-144.
6. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
7. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.
8. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
9. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
10. Condit, R. C., R. Easterly, R. F. Pacha, Z. Fathi, and R. J. Meis. 1991. A vaccinia virus isatin-beta-thiosemicarbazone resistance mutation maps in the viral gene encoding the 132-kDa subunit of RNA polymerase. Virology 185:857-861.
11. De Clercq, E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:569-596.
12. De Clercq, E., and A. Holy. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4:928-940.
13. Franklin, M. C., J. Wang, and T. A. Steitz. 2001. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 105:657-667.
14. Geerinck, K., G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, Y. Vanrenterghem, H. Degreef, and B. Maes. 2001. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:543-549.
15. Gibbs, J. S., H. C. Chiou, K. F. Bastow, Y. C. Cheng, and D. M. Coen. 1988. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc. Natl. Acad. Sci. USA 85:6672-6676.
16. Hamilton, M. D., and D. H. Evans. 2005. Enzymatic processing of replication and recombination intermediates by the vaccinia virus DNA polymerase. Nucleic Acids Res. 33:2259-2268.
17. Kinchington, P. R., T. Araullo-Cruz, J. P. Vergnes, K. Yates, and Y. J. Gordon. 2002. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antivir. Res. 56:73-84.
18. Magee, W. C., K. Y. Hostetler, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162.
19. McCabe, D., B. Weston, and G. Storch. 2003. Treatment of orf poxvirus lesion with cidofovir cream. Pediatr. Infect. Dis. J. 22:1027-1028.
20. Meadows, K. P., S. K. Tyring, A. T. Pavia, and T. M. Rallis. 1997. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 133:987-990.
21. Meis, R. J., and R. C. Condit. 1991. Genetic and molecular biological characterization of a vaccinia virus gene which renders the virus dependent on isatin-beta-thiosemicarbazone (IBT). Virology 182:442-454.
22. NettIeton, P. F., J. A. Gilray, H. W. Reid, and A. A. Mercer. 2000. Parapox-viruses are strongly inhibited in vitro by cidofovir. Antivir. Res. 48:205-208.
23. Pacha, R. F., and R. C. Condit. 1985. Characterization of a temperature-sensitive mutant of vaccinia virus reveals a novel function that prevents virus-induced breakdown of RNA. J. Virol. 56:395-403.
24. Parker, R. F., L. H. Bronson, and R. H. Green. 1941. Further studies of the infectious unit of vaccinia. J. Exp. Med. 74:263-281.
25. Shamoo, Y., and T. A. Steitz. 1999. Building a replisome from interacting pieces: sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex. Cell 99:155-166.
26. Smee, D. F., B. B. Barnett, R. W. Sidwell, E. J. Reist, and A. Holy. 1995. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antivir. Res. 26:1-9.
27. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
28. Smee, D. F., M. K. Wandersee, K. W. Bailey, K. Y. Hostetler, A. Holy, and R. W. Sidwell. 2005. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir. Chem. Chemother. 16:203-211.
29. Snoeck, R., G. Andrei, and E. De Clercq. 1996. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 15:574-579.
30. Snoeck, R., T. Sakuma, E. De Clercq, I. Rosenberg, and A. Holy. 1988. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
31. Spacciapoli, P., and N. G. Nossal. 1994. A single mutation in bacteriophage T4 DNA polymerase (A737V, tsL141) decreases its processivity as a polymerase and increases its processivity as a 3′-→5′ exonuclease. J. Biol. Chem. 269:438-446.
32. Spicer, E. K., J. Rush, C. Fung, L. J. Reha-Krantz, J. D. Karam, and W. H. Konigsberg. 1988. Primary structure of T4 DNA polymerase. Evolutionary relatedness to eucaryotic and other procaryotic DNA polymerases. J. Biol. Chem. 263:7478-7486.
33. Stanitsa, E. S., L. Arps, and P. Traktman. 2006. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem. 281:3439-3451.
34. Stittelaar, K. J., L. S. Wyatt, R. L. de Swart, H. W. Vos, J. Groen, G. van Amerongen, R. S. van Binnendijk, S. Rozenblatt, B. Moss, and A. D. Osterhaus. 2000. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74:4236-4243.
35. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
36. Taddie, J. A., and P. Traktman. 1993. Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3′-5′ exonuclease domain. J. Virol. 67:4323-4336.
37. Van Rompay, K. K., R. P. Singh, L. L. Brignolo, J. R. Lawson, K. A. Schmidt, B. Pahar, D. R. Canfield, R. P. Tarara, D. L. Sodora, N. Bischofberger, and M. L. Marthas. 2004. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J. Acquir. Immune Defic. Syndr. 36:900-914.
38. Weber, J., B. Chakraborty, J. Weberova, M. D. Miller, and M. E. Quinones-Mateu. 2005. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol. 43:1395-1400.
39. Yang, G., J. Wang, and W. Konigsberg. 2005. Base selectivity is impaired by mutants that perturb hydrogen bonding networks in the RB69 DNA polymerase active site. Biochemistry 44:3338-3346.